SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation L24E

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials


1 Influence of Corifollitropin Alfa (Elonva) on Embryo Morphokinetics and Fertility Treatment Outcome

The study evaluates the influence of corifollitropin alfa (Elonva) on embryo morphokinetics and fertility treatment outcome in comparison to a control group stimulated with Follitropin beta (Puregon).

NCT04142190 Infertility Drug: ELONVA Drug: PUREGON
MeSH: Infertility
HPO: Infertility

Follicular fluid (FF) were examined for oocytes under constant conditions of 37 °C in an IVF workstation L24E with heating stage (K-SYSTEMS Kivex Biotec A/S). --- L24E ---

Primary Outcomes

Description: Time of pronuclei disappearance in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Time of pronuclei disappearance

Time: 16-18 hours after fertilization

Description: The first observation of two discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Two discrete cells

Time: 26-28 hours after fertilization

Description: The first observation of three discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Three discrete cells

Time: 28-44 hours after fertilization

Description: The first observation of four discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Four discrete cells

Time: 44-45 hours after fertilization

Description: The first observation of five discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Five discrete cells

Time: 44-68 hours after fertilization

Description: The first observation of six discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Six discrete cells

Time: 44-68 hours after fertilization

Description: The first observation of seven discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Seven discrete cells

Time: 44-68 hours after fertilization

Description: The first observation of eight discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Eight discrete cells

Time: 68-69 hours after fertilization

Description: The first observation of nine discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Nine discrete cells

Time: 69-92 hours after fertilization

Description: End of the compaction process; when observable compaction is complete in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON

Measure: Morula stage

Time: 92 hours after fertilization

Secondary Outcomes

Description: The influence of ELONVA versus PUREGON on the number of oocytes retrieved will be assessed.

Measure: Number of oocytes retrieved

Time: Number of oocytes retrieved will be evaluated after one treatment cycle (each cycle is between 28 and 35 days)

Description: The influence of ELONVA versus PUREGON on the maturity stage of oocytes (germinal vesicle, metaphase I (MI) or MII phase) retrieved will be assessed.

Measure: Stage of oocyte development

Time: Stage of oocytes retrieved will be evaluated after one treatment cycle (each cycle is between 28 and 35 days)

Description: The influence of ELONVA versus PUREGON on the number of fertilized oocytes will be assessed.

Measure: Fertilized oocytes

Time: Number of fertilized oocytes will be evaluated after one treatment cycle (each cycle is between 28 and 35 days)

Description: The influence of ELONVA versus PUREGON on embryo grading (Istanbul consensus criteria) will be assessed. The grading consists of assessment of cell number, fragmentation, multinucleation, cell size, cytoplasmic granularity, membrane appearance, and the presence of vacuoles).

Measure: Embryo grading

Time: The quality of embryos will be evaluated after one treatment cycle (each cycle is between 28 and 35 days)

Description: The influence of Elonva versus Puregon on the number of biochemical pregnancies will be assessed.

Measure: Biochemical pregnancy (measurement of beta hCG)

Time: Biochemical pregnancies will be evaluated after successful implantation (1 week after embryo transfer)

Description: The influence of Elonva versus Puregon on the number of life births will be assessed.

Measure: Life birth

Time: Life births will be evaluated after successful pregnancy (9 moths after embryo transfer)

Description: The influence of Elonva versus Puregon on the weight of the newborn will be assessed.

Measure: Weight (kilograms)

Time: Weight of the newborn will be evaluated after birth (9 moths after embryo transfer)

Description: The influence of Elonva versus Puregon on the height of the newborn will be assessed.

Measure: Height (centimeters)

Time: Height of the newborn will be evaluated after birth (9 moths after embryo transfer)


HPO Nodes


Infertility
Genes 206
DNAH9 SNORD116-1 VAMP7 DNAH11 HJV PGR AXL SPAG1 PMFBP1 AR ADGRG2 SOX9 SEMA3E DNAAF3 GAS2L2 CCDC151 OTX2 STRC CFAP300 ZP3 ZMYND10 GATA4 HSD17B3 MKRN3 PMFBP1 DNAH1 CATSPER2 FSHB RSPH4A CFTR DUSP6 TEX11 NME8 DNAAF4 CEP19 SRY CCDC65 NR5A1 PROP1 HESX1 CFAP300 DNAI1 CDC14A MAP3K1 NR3C1 RSPH1 DNAH1 CCDC39 PWRN1 DNAL1 PATL2 GBA2 ZMYND10 LRRC6 FOXA2 QRICH2 CTNS DNAAF1 ZFPM2 GAS8 CFAP298 CFAP298 HSD17B3 CDH23 RBMY1A1 NR3C1 CATSPER2 GBA2 RNF216 ZP2 RSPH3 DNAAF2 PLCZ1 CCNO SRA1 DNAAF1 CCDC40 ZP1 TSGA10 DMRT3 DNAAF4 SNORD115-1 DNAH9 DNAI1 SRY DNAAF6 DNAH5 GCM2 DHH AR TTC25 FCGR2A FOXL2 SPEF2 IL17RD DNAAF5 HERC2 TEX14 CYP19A1 WWOX SNRPN AMHR2 ARMC4 FLRT3 NANOS1 IPW STRC SOHLH1 FANCA PROP1 DAZ2 MEI1 NPAP1 LMNA WDR11 HUWE1 CFAP221 KLHL10 PLIN1 DNAI2 TLE6 AMH PANX1 LHX4 GLI2 PRLR POLR3B WEE2 PADI6 DNAAF5 DAZ4 POU1F1 ARMC2 FGF17 STUB1 FOXJ1 SUN5 CFAP43 MAP2K1 CCNO FEZF1 DAZ3 TSPY1 RSPH1 DNAJB13 STK36 BRAF AURKC USP8 DNAH1 RSPH3 RSPH9 FSIP2 DRC1 LHCGR WDR66 CCDC103 TUBB8 AR DNAAF3 NDN LRRC56 LRRC6 MAGEL2 CCDC40 SOX3 MKRN3-AS1 SPRY4 DDX3Y PWAR1 SLC26A8 USP9Y DNAAF6 STRC GAS2L2 TGFB1 GNRH1 SPATA16 CCDC39 CDH23 PRLR H6PD WT1 NR0B1 OFD1 CFAP44 BRDT ZMPSTE24 MEIOB DNAI2 SEPTIN12 GNRHR CFTR CCDC141 PTPN11 CCDC114 DAZ1 PPP2R3C DNAJB13 RPGR CATSPER2 AK7 SUN5 CATSPER1 MCIDAS HYDIN